Skip to Content

CCS Launches AI-powered model

CCS Launches AI-powered model

CCS Launches AI-powered model

Richard MackeyDALLAS – CCS has launched PropheSee, an AI-powered predictive model for healthcare organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device. 

With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk classification, along with the timely delivery of patient-specific information and insights that support long-term therapy adherence. 

"CCS can now proactively identify if a member is at a higher risk of falling off therapy, and then take action based on individual specific insights to best support them in maintaining adherence," said Richard Mackey, chief technology officer at CCS. "The launch of PropheSee reinforces our commitment at CCS to deliver a smarter, more personalized approach to keeping people on therapy - resulting in healthier members and lower cost for the healthcare ecosystem.” 

In addition to improved clinical outcomes, health plans and risk-bearing providers can also realize savings of up to $2,200 per patient per year from this increase in CGM adherence and better glycemic control. 

CCS’ dataset - which includes decades of proprietary patient behavior data - paints a significantly more holistic picture of an individual’s health and well-being versus claims data, which is often delayed and not fully reflective of their journey. Also of note, patient-level social determinants of health data and insights round out a more comprehensive view of each patient and empower healthcare organizations to proactively identify those most at risk of falling off therapy.  

“The innovative, advanced analytics predictive model that Accenture collaborated with CCS to develop will help identify patients at risk of non-adherence to diabetic treatment up to 90 days in advance,” said Chinmoy Barua, managing director of Data & AI at Accenture. “Taking real-time, personalized action, the tool intends to drive better adherence and improved outcomes. Trusted studies suggest that better engagement with patients leads to better health outcomes and overall quality of life.”


To comment on this post, please log in to your account or set up an account now.